3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
149
Docetaxel
138
Paclitaxel
127
Trastuzumab
119
Tamoxifen
110
Capecitabine
104
Letrozole
92
Epirubicin
79
Doxorubicin
70
Anastrozole
70
exemestane
67
Fulvestrant
65
Fluorouracil
61
Radiotherapy
60
pertuzumab
40
Gemcitabine
39
Carboplatin
38
Vinorelbine
34
Goserelin
34
Bevacizumab
29
Zoledronic Acid
28
Methotrexate
28
Chemotherapy, Adjuvant
28
eribulin
27
Lapatinib
25
ribociclib
24
palbociclib
24
Drug Therapy
22
130-nm albumin-bound paclitaxel
20
pegfilgrastim
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Breast Neoplasms
×
Mebendazole
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn